A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)

No open prediction endpoints

Endpoints are classified and published by ProgramSignal analysts.

Key Facts

Primary Endpoints (CT.gov)

Eligibility Criteria

Inclusion Criteria: * Male patients diagnosed with metastatic prostate cancer * Initiated apalutamide or enzalutamide for the first-line treatment of metastatic castration-sensitive prostate cancer (mCSPC). Initiation date of first treatment defines the index date. * Index date on or after 1 January 2020 * Evidence of androgen deprivation therapy (ADT) use between 90 days prior to the index date and 6 months following the index date * Age ≥18 years on the index date -≥6 months of clinical activity following the index date, unless the patient died Exclusion Criteria: * Evidence of castration-resistance prior to the index date * Received chemotherapy, androgen receptor pathway inhibitor, radiopharmaceuticals, immunotherapy, PARP inhibitor, or estrogens prior to the index date * Evidence of ADT use between 1 year and 91 days prior to the index date * Had a prior history of other cancers

✦ Analyst Commentary

Expert commentary on why this trial matters and what to watch for.

Source